Table 1 Baseline characteristics according to GGT
Total population (n = 140) | GGT < 56 U/L (n = 98) | GGT ≥56 U/L (n = 42) | P value | |
|---|---|---|---|---|
Age (years) | 56.2 ± 13.1 | 56.1 ± 13.0 | 56.5 ± 13.4 | 0.540 |
Male | 105 (75.0%) | 65 (66.3%) | 40 (95.2%) | < 0.001 |
BMI (Kg·m− 2) | 24.2 ± 2.4 | 24.2 ± 2.2 | 24.4 ± 2.7 | 0.858 |
Primary prevention | 25 (17.9%) | 16 (16.3%) | 9 (21.4%) | 0.470 |
Ischemic cardiomyopathy | 36 (25.7%) | 22 (22.4%) | 14 (33.3%) | 0.177 |
Hypertension | 31 (22.1%) | 24 (24.5%) | 7 (16.7%) | 0.307 |
Diabetes | 4 (2.9%) | 3 (3.1%) | 1 (2.4%) | 0.825 |
Atrial fibrillation | 10 (7.1%) | 5 (5.1%) | 5 (11.9%) | 0.152 |
QRS duration | 112.49 ± 26.89 | 111.40 ± 26.27 | 115.72 ± 29.19 | 0.559 |
LVEF (%) | 44.9 ± 14.7 | 46.6 ± 14.6 | 40.9 ± 14.4 | 0.034 |
LVEDD (mm) | 57.1 ± 13.3 | 55.9 ± 13.0 | 60.0 ± 13.7 | 0.094 |
NYHA class I-II | 95 (67.9%) | 71 (72.5%) | 24 (57.1%) | 0.077 |
ACEI or ARB | 74 (52.9%) | 57 (58.2%) | 17 (40.5%) | 0.055 |
Beta-blocker | 122 (87.1%) | 86 (87.6%) | 36 (85.7%) | 0.741 |
Amiodarone | 80 (57.1%) | 56 (57.1%) | 24 (57.1%) | 1.000 |
Spironolactone | 76 (54.3%) | 44 (44.9%) | 32 (76.2%) | 0.001 |
Digoxin | 38 (27.1%) | 26 (26.5%) | 12 (28.6%) | 0.803 |
Diuretic | 84 (60.0%) | 53 (54.1%) | 31 (73.8%) | 0.029 |
Statins | 50 (35.7%) | 39 (39.8%) | 11 (26.2%) | 0.124 |
hsCRP (mg·L−1) | 4.61 ± 4.74 | 3.58 ± 4.06 | 7.03 ± 5.42 | < 0.001 |
eGFR (mL·min−1·1.73 m−2) | 80.0 ± 24.5 | 81.8 ± 24.8 | 75.8 ± 23.5 | 0.189 |
FBG (mmol·L−1) | 5.34 ± 1.20 | 5.14 ± 1.00 | 5.80 ± 1.50 | 0.011 |
HDL (mmol·L−1) | 1.03 ± 0.36 | 1.13 ± 0.31 | 1.07 ± 0.47 | 0.365 |
LDL (mmol·L−1) | 2.45 ± 0.73 | 2.44 ± 0.74 | 2.47 ± 0.74 | 0.849 |
Triglyceride (mmol·L−1) | 1.51 ± 0.84 | 1.51 ± 0.89 | 1.53 ± 0.74 | 0.514 |